Published in Pharma Investments, Ventures and Law Weekly, December 10th, 2006
Key financial highlights are as follows:
Third Quarter 2006:
- Revenue increased by $6.1 million, or 32%, to $25.1 million, compared to the third quarter of 2005.
- GAAP diluted earnings per share, which includes an incremental litigation settlement expense of $544,000 and stock-based compensation expenses, was $0.21. Non-GAAP(1) diluted earnings per share was $0.30.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly